Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion
French biotech Ipsen is acquiring Kartos Therapeutics in a deal valued at up to $1.75 billion to expand its hemato-oncology pipeline.
📍 How it ended
Ipsen agreed to acquire Kartos Therapeutics for $450 million upfront, with the total deal valued up to $1.75 billion. The acquisition aimed to expand Ipsen's late-stage hemato-oncology pipeline and included a blood cancer asset intended as a potential Jakafi add-on therapy for myelofibrosis.
Epilogue added 89d ago, after coverage quieted.
Coverage (6)
-
-
-
-
-
-
Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion WSJ · 96d ago broke it first
Where it stands
- Velocity & Diffusion: Coverage escalated across 6 distinct news outlets with 6 published articles, achieving a live velocity of 4.
- Primary Driver: French biotech Ipsen is acquiring Kartos Therapeutics in a deal valued at up to $1.75 billion to expand its hemato-oncology pipeline.
- Predictive Outlook: Newsylist algorithmic models forecast this story will fade from trending status over the next 24 hours.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
Ipsen has entered an agreement to acquire Kartos Therapeutics. The deal includes an upfront payment of $450 million, with total potential value reaching up to $1.75 billion.
Coverage from Reuters, The Wall Street Journal, and Endpoints News emphasizes the financial terms of the acquisition. Fierce Biotech and GlobeNewswire note that the move expands Ipsen's late-stage hemato-oncology pipeline, specifically regarding a potential Jakafi add-on therapy for myelofibrosis.
Future developments center on the integration of Kartos' blood cancer research and the progress of the myelofibrosis therapy.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 96d ago.
Answered
How much is Ipsen paying for Kartos Therapeutics?
The deal involves an upfront payment of $450 million, with a total potential value of up to $1.75 billion.
What is the primary therapeutic goal of this acquisition?
Ipsen aims to expand its late-stage hemato-oncology pipeline, including a potential add-on therapy for myelofibrosis to be used with Jakafi.
What type of company is Ipsen?
According to Reuters, Ipsen is a French biotech company.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.
People, places & organizations
Topics
Related trends
The Surprising Reason This Biotech Plummeted 69%
EyePoint Pharmaceuticals shares cratered following a late-stage trial setback for its flagship eye disease drug.
MapLight shares sink on mixed ph. 2 schizophrenia readout
7 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.
FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics shares are plummeting after FDA staff disputed the company's claims of Phase 3 success for its DMD cell therapy.
Argenx to Buy Forte Biosciences for $2.2 Billion
8 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.
The 'Surprisingly Soft' Unit That Caused Danaher To Plummet
Danaher shares slide despite second-quarter earnings and revenue beats, driven by softness in its biotech unit.
Lilly Said to Near Deal for Psychedelic Drugmaker AtaiBeckley
Eli Lilly is reportedly nearing an acquisition of the psychedelic drugmaker AtaiBeckley, triggering significant movement in the company's share price.